S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Sell every Stock except ONE (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Invest in Smart Home Tech with Superior Patents (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Invest in Smart Home Tech with Superior Patents (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Sell every Stock except ONE (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Invest in Smart Home Tech with Superior Patents (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Invest in Smart Home Tech with Superior Patents (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Sell every Stock except ONE (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Invest in Smart Home Tech with Superior Patents (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Invest in Smart Home Tech with Superior Patents (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Sell every Stock except ONE (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Invest in Smart Home Tech with Superior Patents (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
Invest in Smart Home Tech with Superior Patents (Ad)pixel
NASDAQ:GH

Guardant Health - GH Stock Forecast, Price & News

$53.17
-1.87 (-3.40%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$51.23
$54.54
50-Day Range
$35.88
$55.04
52-Week Range
$27.65
$133.82
Volume
745,469 shs
Average Volume
1.04 million shs
Market Capitalization
$5.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$119.00

Guardant Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
123.8% Upside
$119.00 Price Target
Short Interest
Healthy
4.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.30mentions of Guardant Health in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$240,210 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.79) to ($5.28) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

326th out of 1,124 stocks

Medical Laboratories Industry

9th out of 28 stocks

GH stock logo

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Guardant Health Price Performance

Guardant Health stock traded down $1.87 on Tuesday, reaching $53.17. The company's stock had a trading volume of 745,469 shares, compared to its average volume of 1,265,628. The business's fifty day moving average price is $46.33 and its 200 day moving average price is $54.00. The company has a debt-to-equity ratio of 3.56, a quick ratio of 5.83 and a current ratio of 6.18. The company has a market cap of $5.44 billion, a price-to-earnings ratio of -9.83 and a beta of 0.81. Guardant Health has a twelve month low of $27.65 and a twelve month high of $133.82.

Guardant Health (NASDAQ:GH - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($1.00). The company had revenue of $109.14 million for the quarter, compared to analyst estimates of $105.14 million. Guardant Health had a negative return on equity of 99.90% and a negative net margin of 135.03%. The firm's quarterly revenue was up 18.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.96) EPS. Equities analysts expect that Guardant Health will post -5.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently weighed in on GH. Citigroup decreased their price target on Guardant Health from $120.00 to $100.00 in a report on Friday, May 6th. Piper Sandler began coverage on shares of Guardant Health in a research report on Thursday, June 2nd. They set an "overweight" rating and a $65.00 price target on the stock. Morgan Stanley cut their price target on Guardant Health from $85.00 to $80.00 and set an "overweight" rating on the stock in a research note on Monday, August 8th. The Goldman Sachs Group decreased their price target on Guardant Health from $90.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, August 8th. Finally, OTR Global cut shares of Guardant Health to a "positive" rating in a report on Monday, August 1st. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $119.00.

Insider Activity

In other news, SVP Amelia Merrill sold 4,500 shares of the business's stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $53.38, for a total transaction of $240,210.00. Following the completion of the sale, the senior vice president now owns 24,708 shares in the company, valued at $1,318,913.04. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock News Headlines

Why Guardant Health Stock Was So Healthy Today
Why Shares of Guardant Health Dropped 33.6% in May
What 6 Analyst Ratings Have To Say About Guardant Health
Why Guardant Health Stock Is Crashing Today
Guardant Health Q1 2022 Earnings Preview
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings
8/04/2022
Today
8/17/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
1,373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$119.00
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$65.00
Forecasted Upside/Downside
+123.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-405,670,000.00
Net Margins
-135.03%
Pretax Margin
-130.34%

Debt

Sales & Book Value

Annual Sales
$373.65 million
Book Value
$3.12 per share

Miscellaneous

Free Float
96,189,000
Market Cap
$5.44 billion
Optionable
Not Optionable
Beta
0.81

Key Executives

  • Dr. Helmy Eltoukhy Ph.D. (Age 43)
    Co-Founder, Co-CEO & Chairman
    Comp: $13.66k
  • Dr. AmirAli Talasaz Ph.D. (Age 42)
    Co-CEO & Director
    Comp: $13.27k
  • Mr. Michael Bell (Age 53)
    Chief Financial Officer
    Comp: $1.2M
  • Mr. John G. Saia (Age 49)
    Chief Legal Officer
    Comp: $641.22k
  • Dr. Craig Eagle M.D. (Age 55)
    Chief Medical Officer
    Comp: $2.88M
  • Mr. Christopher Freeman (Age 48)
    Chief Commercial Officer of Oncology Bus.
    Comp: $740.23k
  • Mr. Andy Ament
    Sr. VP of Operations
  • Darya Chudova
    Sr. VP of Technology
  • Mr. Kumud Kalia
    Chief Information Officer
  • Ms. Jennifer Higgins
    VP of Public Affairs













GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price forecast for 2022?

12 brokers have issued 1-year price objectives for Guardant Health's stock. Their GH share price forecasts range from $65.00 to $165.00. On average, they anticipate the company's share price to reach $119.00 in the next twelve months. This suggests a possible upside of 123.8% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2022?

Guardant Health's stock was trading at $100.02 on January 1st, 2022. Since then, GH shares have decreased by 46.8% and is now trading at $53.17.
View the best growth stocks for 2022 here
.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our GH earnings forecast
.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) announced its earnings results on Thursday, August, 4th. The company reported ($2.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.25) by $1.00. The business had revenue of $109.14 million for the quarter, compared to analyst estimates of $105.14 million. Guardant Health had a negative net margin of 135.03% and a negative trailing twelve-month return on equity of 99.90%. The business's quarterly revenue was up 18.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.96) EPS.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.29 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an IPO on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by many different retail and institutional investors. Top institutional investors include Clearbridge Investments LLC (3.17%), Price T Rowe Associates Inc. MD (1.54%), Pictet Asset Management SA (1.01%), Massachusetts Financial Services Co. MA (0.98%), Northern Trust Corp (0.41%) and Integral Health Asset Management LLC (0.38%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $53.17.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $5.44 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis.

How many employees does Guardant Health have?

The company employs 1,373 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.